Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes

MedGenMed Medscape General Medicine

Volumn 9, Issue 2, 2007, Pages

  Levy, Philip ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; LONG ACTING DRUG; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; UNINDEXED DRUG; VILDAGLIPTIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

ALGORITHM; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CHOICE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INDIVIDUALIZATION; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; OUTPATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT PLANNING; WEIGHT GAIN; CLINICAL PRACTICE; DRUG COMBINATION; ORAL DRUG ADMINISTRATION; STANDARD; UNITED STATES;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 34247155434     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. National Diabetes Awareness Month - November, 2006. MMWR Weekly. 2006;55:1169. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5543a1.htm Accessed January 16, 2007.
2. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936-1940. abstract
3. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. NIH Publication No. 06-3892. Available at: http:// diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm Accessed August 4, 2006.
4. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23:1278-1283. abstract
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986. abstract
6. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853. abstract
7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117. abstract
8. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653. abstract
9. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349. abstract
10. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88. abstract
11. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711-1721. abstract
12. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30:S4-S41. abstract
13. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management -2000 update. Endocr Pract. 2000;6:43-84. abstract
14. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20. abstract
15. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-278. abstract
16. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822-1826. abstract
17. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care. 2003;26:881-885. abstract
18. Davidson JA, Blonde L, Jellinger PS, Lebovitz HE, Parkin CG. Road map for the prevention and treatment of type 2 diabetes. ACE/AACE Diabetes Road Map Task Force. Available at: http://www.aace.com/meetings/ consensus/odimplementation/roadmap.pdf. Accessed August 1, 2006.
19. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract. 2005;68:S22-S29. abstract
20. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-372. Abstract
21. Holman RR. Long-term efficacy of sulfonylureas: A United Kingdom Prospective Diabetes Study perspective. Metabolism. 2006;55:S2-S5.
22. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385-411. abstract
23. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086. abstract
24. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. abstract
25. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006;12:6-12. abstract
26. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336. abstract
27. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012. abstract
28. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998;15:297-303. abstract
29. Eldor R, Stern E, Milicevic Z, Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract. 2005;68:S30-S35. abstract
30. Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord. 2002;26:S25-30.
31. Mooradian AD, Bernbaum M, Albert SG. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125-134. abstract
32. Riddle MC. Making the transition from oral to insulin therapy. Am J Med. 2005;118:14S-20S.
33. Fritsche A, Haring H-U, Togel E, Schweitzer M-A. Treat-to-target with add-on basal insulin - can insulin glargine reduce the barrier to target attainment? Diabetes. 2003;52:A119.
34. Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Farn Pract. 2005;18:199-204. abstract
35. Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31:4S7-4S24. Abstract
36. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673-682. abstract
37. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab. 2005;31:7-13. abstract
38. Mathieu C. Can we reduce hypoglycaemia with insulin detemir? Int J Obes Relat Metab Disord. 2004;28:S35-S40.
39. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs. 2005;65:325-340. abstract
40. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174-183. Abstract
41. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med. 2002;113:308-316. abstract
42. Heinemann L. Overcoming obstacles: new management options. Eur J Endocrinol. 2004;151:T23-T27. abstract
43. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27:1113-1125. abstract
44. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8:58-66. abstract
45. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-451. abstract
46. Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1-8. Abstract
47. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955. abstract
48. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274. abstract
49. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64. abstract
50. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. [Correction appears in Raslova K, et al. Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract. 2004;66:193-201. abstract
51. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63:1743-1778. abstract
52. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord. 2004;28:S23-S28. abstract
53. Rosenstock J, Davies M, Home PD, Larsen J, Tamer SC, Schernthanr G. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes. 2006;55(suppl 1):A132.
54. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66:31-49. Abstract
55. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38:1357-1362. abstract
56. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia. 2006;49:1163-1168. abstract
57. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265. abstract
58. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527-532. abstract
59. Raskin P, Braceras R, Schwartz S, Chaykin L, Pei-Ling C, Wynne A. Over 75% of patients with type 2 diabetes reached target A1C by adding biphasic insulin aspart 70/30 to optimized metformin and pioglitazone treatment. Diabetes. 2006;55:A131.
60. Liebl A, Prager R, Kaiser M, Binz K, Gallwitz B. Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: the PREFER study. Diabetes. 2006;55:A123.
61. Malone A Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034-2044. abstract
62. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381. abstract
63. Sun P, Wang R, Jacober SJ. Therapeutic effectiveness of two insulin regimens for insulin naive patients with type 2 diabetes mellitus: once-daily basal insulin or twice-daily premixed insulin. Diabetes. 2006;55:A101.
64. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259. abstract
65. Linnebjerg H, Kothare PA, Skrivanek Z, et al. Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med. 2006;23:240-245. abstract
66. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569. abstract
67. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233-242. abstract
68. Salehi M, D'Alessio DA. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med. 2006;73:382-389. Abstract
69. Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs. 2006;15:431-442. abstract
70. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. 2006;26:360-374. abstract
71. Odegard PS, Capoccia KL. Inhaled insulin: Exubera. Ann Pharmacother. 2005;39:843-853. abstract
72. Raskin P. Can glycemic targets be achieved - in particular with two daily injections of a mix of intermediate- and short-acting insulin? Endocr Pract. 2006;12:52-54.
73. Rizvi AA. Type 2 diabetes: epidemiologic trends, evolving pathogenetic concepts, and recent changes in therapeutic approach. South Med J. 2004;97:1079-1087. abstract
74. Meece J. Pharmacoeconomic advantages of insulin analogs. US Pharm. 2006;31:HS42-50. Available at: http://www.uspharmacist.com/ index.asp?show=article&page=8_1920.htm Accessed January 8, 2007.
75. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2005;59:1345-1355. abstract
76. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:9S-18S. abstract
77. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-1224. abstract
78. Schwartz S, Khutoryansky N, Braceras R. Comparison of resource utilization, preference, and handling of pre-filled pen and vial/syringe in patients with type 2 diabetes mellitus. J Clin Res. 2006;9:21-30.
79. Asakura T, Seino H, Jensen KH. NovoPen[R] 4 is easier to teach, more intuitive to use and preferred by patients compared to OptiClik[R]. Diabetes. 2006;55:A456.
80. Garber AJ. Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes. Clin Ther. 2005;27:S39-S41.
81. Chapman TM, Perry CM. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs. 2005;19:67-69. abstract
82. Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15:496-502. abstract
83. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR, 2006.